IQVIA Holdings/$IQV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About IQVIA Holdings
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Ticker
$IQV
Sector
Primary listing
NYSE
Industry
Life Sciences Tools & Services
Headquarters
Employees
89,000
ISIN
US46266C1053
Website
IQVIA Holdings Metrics
BasicAdvanced
$27B
21.45
$7.35
1.29
-
Price and volume
Market cap
$27B
Beta
1.29
52-week high
$249.97
52-week low
$134.65
Average daily volume
2.5M
Financial strength
Current ratio
0.823
Quick ratio
0.723
Long term debt to equity
221.972
Total debt to equity
242.907
Interest coverage (TTM)
3.41%
Profitability
EBITDA (TTM)
2,926
Gross margin (TTM)
34.72%
Net profit margin (TTM)
8.61%
Operating margin (TTM)
14.73%
Effective tax rate (TTM)
19.00%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
5.29%
Return on equity (TTM)
21.64%
Valuation
Price to earnings (TTM)
21.454
Price to revenue (TTM)
1.828
Price to book
4.59
Price to tangible book (TTM)
-2.02
Price to free cash flow (TTM)
13.096
Free cash flow yield (TTM)
7.64%
Free cash flow per share (TTM)
1,203.34%
Growth
Revenue change (TTM)
2.84%
Earnings per share change (TTM)
0.26%
3-year revenue growth (CAGR)
3.36%
10-year revenue growth (CAGR)
13.97%
3-year earnings per share growth (CAGR)
9.88%
10-year earnings per share growth (CAGR)
10.45%
What the Analysts think about IQVIA Holdings
Analyst ratings (Buy, Hold, Sell) for IQVIA Holdings stock.
Bulls say / Bears say
IQVIA's Technology & Analytics Solutions (TAS) segment reported a 9.5% revenue increase in Q4 2024, indicating strong demand for its analytics services. (IQVIA Press Release)
The company achieved a 41% year-over-year growth in free cash flow, reaching $2.11 billion in 2024, enhancing its capacity for strategic investments and shareholder returns. (IQVIA Press Release)
IQVIA's R&D Solutions contracted backlog grew to $31.1 billion as of December 31, 2024, up 5.5% year-over-year at constant currency, suggesting sustained future revenue streams. (IQVIA Press Release)
The Research & Development Solutions (R&DS) segment experienced a 1.3% revenue decline in Q4 2024, indicating potential challenges in this key business area. (IQVIA Press Release)
IQVIA's GAAP Net Income for Q4 2024 declined by 6.8% year-over-year, which may raise concerns about profitability trends. (IQVIA Press Release)
The Contract Sales & Medical Solutions (CSMS) segment saw a 4.8% revenue decrease in Q4 2024, reflecting challenges in this part of the business. (IQVIA Press Release)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
IQVIA Holdings Financial Performance
Revenues and expenses
IQVIA Holdings Earnings Performance
Company profitability
IQVIA Holdings News
AllArticlesVideos
IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025
Business Wire·5 hours ago
IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement'
Business Wire·2 weeks ago
IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap?
Benzinga·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for IQVIA Holdings stock?
IQVIA Holdings (IQV) has a market cap of $27B as of July 01, 2025.
What is the P/E ratio for IQVIA Holdings stock?
The price to earnings (P/E) ratio for IQVIA Holdings (IQV) stock is 21.45 as of July 01, 2025.
Does IQVIA Holdings stock pay dividends?
No, IQVIA Holdings (IQV) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next IQVIA Holdings dividend payment date?
IQVIA Holdings (IQV) stock does not pay dividends to its shareholders.
What is the beta indicator for IQVIA Holdings?
IQVIA Holdings (IQV) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.